PROTHENA CORP PUBLIC LTD CO — Investor Relations & Filings
Filings indexed
958
across all filing types
Latest filing
2026-05-15
Regulatory Filings
Country
US
United States of America
Listing
US
PRTA
Prothena Corporation is a late-stage clinical biotechnology company specializing in the science of protein dysregulation. The company leverages its expertise in the biology of misfolded proteins to discover and develop novel therapeutics. Its primary focus is on advancing a diverse pipeline of investigational treatments for neurodegenerative conditions and rare peripheral amyloid diseases. Prothena's scientific approach integrates insights into neurological dysfunction and the mechanisms of protein misfolding to create antibody-based therapies designed to provide clinically meaningful benefits for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-15 | English | |
| DEF 14A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-03-27 | English | |
| 8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-27 | English | |
| 10-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-27 | English | |
| 8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-19 | English | |
| 8-K | 2025-12-12 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
5 filings
| |||||
| 46362587 | 8-K | 2026-05-15 | English | ||
| 33065546 | DEF 14A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-03-27 | English | ||
| 32893883 | 8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-27 | English | ||
| 32893885 | 10-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-27 | English | ||
| 32893884 | 8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-19 | English | ||
|
2025
10 filings
| |||||
| 12590207 | 8-K | 2025-12-12 | English | ||
| 12590208 | 8-K | 2025-11-19 | English | ||
| 12590209 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 12590210 | Major Shareholding Notification 2025 | 2025-11-12 | English | ||
| 12590211 | Major Shareholding Notification 2025 | 2025-11-12 | English | ||
| 12590212 | 10-Q | 2025-11-06 | English | ||
| 12590213 | DEFA14A | 2025-11-06 | English | ||
| 12590214 | 8-K | 2025-11-06 | English | ||
| 12590215 | Major Shareholding Notification 2025 | 2025-10-17 | English | ||
| 12590216 | DEFA14A | 2025-10-07 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
IMAGION BIOSYSTEMS LIMITED
Develops nanoparticle-based imaging for non-invasive cancer…
|
IBX | AU | Professional, scientific and te… |
|
IMCB PJSC
Biotechnology company specializing in personal stem cell ba…
|
GEMA | RU | Professional, scientific and te… |
|
Immuneering Corp
Clinical-stage oncology company developing medicines using …
|
IMRX | US | Professional, scientific and te… |
|
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Clinical-stage biotech developing dual-approach immuno-onco…
|
1541 | HK | Professional, scientific and te… |
|
IMMUNIC, INC.
Develops oral small molecule therapies for chronic inflamma…
|
IMUX | US | Professional, scientific and te… |
|
Immunovant, Inc.
Clinical-stage immunology company developing anti-FcRn anti…
|
IMVT | US | Professional, scientific and te… |
|
IMMUPHARMA PLC
Specialty biopharmaceutical company developing peptide-base…
|
IMM | GB | Professional, scientific and te… |
|
IMMUTEP LIMITED
Develops LAG-3 targeting immunotherapies for cancer and aut…
|
IMM | AU | Professional, scientific and te… |
|
IMMUTEP Ltd
Biotechnology company developing LAG-3 immunotherapies for …
|
IMMP | US | Professional, scientific and te… |
|
IMPACT BIOMEDICAL INC.
Develops biopharmaceutical products and technologies to pro…
|
IBO | US | Professional, scientific and te… |
PROTHENA CORP PUBLIC LTD CO via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32782/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32782 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32782 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32782 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32782}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PROTHENA CORP PUBLIC LTD CO (id: 32782)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.